Full Archive
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli – IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4’s role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Malignant pleural mesothelioma is a cancer mainly caused by asbestos exposure that is very deadly. Research continues to be done on the cancer, giving hope to patients and their families. One tool in the fight against mesothelioma is ex-vivo models using precision cut tumor slices. A new article looks at ex-vivo models and precision cut…
Malignant pleural mesothelioma is a rare and deadly cancer mainly caused by asbestos exposure. It is hard to surgically remove and is very aggressive, which makes it hard to treat. A trial known as the MARS 2 trial investigated to see if pleurectomy and decortication could improve the quality of life and survival in patients…
Pleural mesothelioma is a cancer mainly caused by asbestos exposure. It is a cancer of the pleura, which is a lining of the lungs. The outlook for the disease is poor, with a typical survival time after diagnosis being 9 to 20 months. The overall five-year survival rate is five percent. These numbers are slightly…
Patient care is improving thanks to artificial intelligence and robotics. One country leading the charge in using technology for healthcare is Vietnam. A study from the Cureus Journal of Medical Sciences looks at AI and robotics improving in Vietnam and how they can help mesothelioma patients in the future. AI is transforming the healthcare industry…
Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure. Two very important aspects of treating mesothelioma are classification and staging. They are important because they guide treatment and predict outcomes. One system to classify cancers is the TNM system which was created by the IASLC. It classifies cancers based on their size and…
Malignant mesothelioma is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs (called the pleura). It is mainly caused by asbestos, and usually occurs 30 to 50 years after initial asbestos exposure. Mesothelioma has a poor outlook, with most patients living only 18 months after diagnosis.…
The aims of this Study are to determine:
How much of the Study Drug (bemcentinib) ends up in urine and faeces
How much of the Study Drug and its breakdown products get into the bloodstream
The breakdown products (metabolites) of the Study Drug
The safety of the Study Drug and any side effects that might be associated with it.
Malignant pleural mesothelioma is an aggressive cancer mainly caused by asbestos exposure. It is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs. The cancer is aggressive and hard to treat. There is hope though in new surgical and therapy methods. A new study looks at…
